Astellas Korea – Jeong Hai-Do, President
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
Astellas Pharma Korea, Inc. is the Korean subsidiary of a leading global pharmaceutical company with outstanding R&D capabilities and a worldwide network.
Astellas has contributed to increasing the quality of life of customers by developing drugs to treat adult diseases and disorders such as urination disturbances common in men, frequent urination commonly in women, overactive bladder syndrome that causes frequent bathroom trips, as well as painful atopic dermatitis. The company also developed Gaster D, a gastroduodenal ulcer treatment drug, which has helped decrease the frequency of gastric ulcer surgery, and Prograf, and immunosuppression agent, which has improved the survival rate of organ transplant recipients.
Astellas Pharma Korea has been growing as a firm, taking pride in its contributions to customer quality of life, and provision of premium medicines in Korea, including Harnal, Vesicare, Prograf, and Protopic Ointment. It also a promising company in the mid-to-long term with many superb products awaiting further development, clinical testing, and launch. Astellas Pharma Korea does not aim to merely expand sales volume, but will continuously increase company value with the goal of maximizing added value for customers and thoseseeking better health, by establishing its Global Category Leader business model.
Contact details
6F 401 Hakdong-ro, Gangnam-gu, Seoul
+82 2 3448 0504
www.astellas.co.kr
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
The CEO of Mega Medical, a Korean medical equipment manufacturer specialized in the ENT area, discusses his firm’s recent expansion into the anti-obesity segment, their strategy for building a global…
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation…
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Tom Roberts came to UCB Korea following a position at the company’s Japanese affiliate in late 2011. He describes the market conditions for UCB’s specialty products and emphasizes the importance…
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Chung Seung, Minister of Food and Drug Safety, discusses the latest improvements to Korea’s regulatory system and highlights vaccines, biosimilars and stem cell research as key components of the country’s…
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Janssen’s managing director in Korea discusses the groups long and significant commitment to R&D in the country, as well as some of the challenges that one of the most innovative…
The founder of MEDIPOST, the producer of the only approved allogenic stem cell product in the world, disucsses their development goals for the coming years and the potential for regenerative…
Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the…
After a lengthy career at Novartis, Angie Kim recently started working at BMS Korea to develop the affiliate. She discusses diversifying the company’s portfolio and their footprint in Korea as…
See our Cookie Privacy Policy Here
